Featured Clinical Trials for Breast Cancer

This large study is designed to see if camizestrant is better than standard treatment after surgery for early-stage, estrogen receptor-positive breast cancer.

This Phase III trial is for premenopausal women who have been diagnosed with early-stage, estrogen receptor-positive, HER2-negative breast cancer. The cancer must have an Oncotype DX Recurrence Score of 25 or less.

This study is looking at whether combining the experimental medicine inavolisib with Phesgo as a first treatment for locally advanced or metastatic HER2-positive breast cancer with a PIK3CA mutation is better than Phesgo alone.

This study is designed to see if an online program can help women better manage pain caused by aromatase inhibitors.

This phase II trial is for people diagnosed with early-stage, estrogen receptor-positive, HER2-negative breast cancer who have inactive cancer cells in their bone marrow after receiving standard breast cancer treatments.

This phase III trial is for people who have been diagnosed with hormone-receptor-positive, HER2-negative breast cancer that has a high risk of coming back.

This phase III trial is for people who have been diagnosed with hormone-receptor-positive, HER2-negative stage I breast cancer with a low risk of coming back.